文献速递肝病消化道肿瘤与早癌

普伐他汀联合索拉非尼未能改善晚期肝细胞癌患者生存

Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2019-05-22

PRODIGE-11试验将323例未接受过系统治疗的Child-Pugh A级晚期肝细胞癌患者随机分为索拉非尼联合普伐他汀组(162例)与索拉非尼单药组(161例),中位随访35个月后,两组中位总生存期分别为10.7个月与10.5个月(HR=1.00,p=0.975),联合治疗未改善生存,主要毒性为腹泻(A组严重腹泻11%,B组8.9%),未报告毒性相关死亡。

要点

  • 索拉非尼联合普伐他汀组与索拉非尼单药组中位总生存期分别为10.7个月与10.5个月,无显著差异(HR=1.00,p=0.975)。
  • 联合治疗未改善无进展生存期、至肿瘤进展时间、至治疗失败时间等次要生存终点。
  • 主要毒性为腹泻,A组严重腹泻11%,B组8.9%,未报告毒性相关死亡。

核心结论

  • 在晚期肝细胞癌患者中,索拉非尼联合普伐他汀未能改善总生存期。

研究设计与样本

  • PRODIGE-11试验为随机对照试验,纳入323例未接受过系统治疗的Child-Pugh A级晚期肝细胞癌患者,随机分为索拉非尼联合普伐他汀组(A组,n=162)与索拉非尼单药组(B组,n=161),主要终点为总生存期。

主要发现

  • 中位随访35个月后,269例患者死亡(A组135例,B组134例),两组中位总生存期分别为10.7个月与10.5个月(HR=1.00,p=0.975),无差异。
  • 次要生存终点(无进展生存期、至肿瘤进展时间、至治疗失败时间)两组间亦无差异。
  • 单因素分析中总生存期的显著预后因素为CLIP评分、体能状态和生活质量评分;多因素分析显示唯一预后因素为CLIP评分。
  • 主要毒性为腹泻,A组严重腹泻发生率为11%,B组为8.9%;严重恶心呕吐罕见,未报告毒性相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). Combining sorafenib with another treatment, to improve overall survival (OS) within an acceptable safety profile, might be the next step forward in the management of patients with advanced HCC. We aimed to assess whether a combination of sorafenib and a statin improved survival in patients with HCC. METHODS: The objective of the PRODIGE-11 trial was to compare the respective clinical outcomes of the sorafenib-pravastatin combination (arm A) versus sorafenib alone (arm B) in patients with advanced HCC. Child-Pugh A patients with advanced HCC who were naive to systemic treatment (n = 323) were randomly assigned to sorafenib-pravastatin combination (n = 162) or sorafenib alone (n = 161). The primary endpoint was OS; secondary endpoints were progression-free survival, time to tumor progression, time to treatment failure, safety, and quality of life. RESULTS: After randomization, 312 patients received at least 1 dose of study treatment. After a median follow-up of 35 months, 269 patients died (arm A: 135; arm B: 134) with no difference in median OS between treatments arms (10.7 months vs. 10.5 months; hazard ratio = 1.00; p = 0.975); no difference was observed in secondary survival endpoints either. In the univariate analysis, the significant prognostic factors for OS were CLIP score, performance status, and quality of life scores. The multivariate analysis showed that the only prognostic factor for OS was the CLIP score. The main toxicity was diarrhea (which was severe in 11% of patients in arm A, and 8.9% in arm B), while severe nausea-vomiting was rare, and no toxicity-related deaths were reported. CONCLUSION: Adding pravastatin to sorafenib did not improve survival in patients with advanced HCC. LAY SUMMARY: Sorafenib has proven efficacy for the treatment of patients with advanced hepatocellular carcinoma. However, overall survival remains poor in these patients, so we were interested to see if the addition of a statin, pravastatin, improved outcomes in patients with advanced HCC. This randomized-controlled trial demonstrated that the sorafenib-pravastatin combination did not improve overall survival in this study population compared to sorafenib alone. Clinical trial number: NCT01075555.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Jouve JL, Lecomte T, Bouché O, et al. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol. 2019. PMID: 31125576. doi:10.1016/j.jhep.2019.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。